May 1, 2012 9:12 AM | 1 min read |
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
AstraZeneca (NYSE: AZN) today announced results of the LUNAR (Limiting UNdertreatment of Lipids in Acute Coronary Syndrome with Rosuvastatin) study, which showed that CRESTOR 40mg significantly decreased LDL-C or “bad” cholesterol and increased HDL-C or “good” cholesterol compared with atorvastatin 80mg in patients with acute coronary syndrome (ACS). ACS is an umbrella term for conditions that result from insufficient blood supply to the heart muscle. The study results, “Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients with Acute Coronary Syndrome (from the LUNAR Study),” were published in the May 1 edition of the American Journal of Cardiology (AJC).
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.